SQUED™ Series 28.1 for Autism
This study is looking at a device called SQUED™ series 28.1, which is used at home. It's designed to help with conditions like autism spectrum disorder. The device works by creating and converting "Autowaves" energy, which are thought to be involved in how the body functions. The study aims to see how well the SQUED™ software works for patients over about one year. You might be able to join if you are between 1 month and 21 years old, have an autism diagnosis or related conditions, and have a history of certain birth traumas like brain injury or lack of oxygen at birth. The study is currently unclear about its recruitment status.
- Study design
- This is an observational study, meaning researchers will observe participants without assigning specific treatments. It plans to enroll 80 participants.
- What's involved
- Participants will use the SQUED™ series 28.1 device at home. The primary endpoint is measured through the SQUED™ software over an average of one year.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured through study completion, an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
At a glance
Conditions
NCT03222375
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics
Lviv, Solonka Village, Urozayna Street 41, Ukrainestudy coordinator listed
Recruiting
World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS
Louisville, Kentuckystudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Yuliya Yaroshuk, M.D.s. Ph.D. · PRINCIPAL_INVESTIGATOR · World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS
- Yuriy Fihol, M.D.s. Ph.D. · PRINCIPAL_INVESTIGATOR · Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- SQUED™ software of patientPersonal Autowave Diagnostics/Personal Autowave Therapy - through study completion, an average of 1 year
This will be administered by Presence of Clinical protocol CRF-SQUED™and creation Active medium SQUED™ for a patient.